Dark

Check out our Dark Pool Levels

RANI
Rani Therapeutics Holdings, Inc. Class A Common Stock
stock NASDAQ

At Close

Jul 22, 2026 3:59:56 PM EDT

0.9000USD+30.159%(+0.2080)6,271,774

0.7900Bid 0.9500Ask 0.1600Spread

Pre-market

Jul 22, 2026 9:28:30 AM EDT

0.7275USD+5.282%(+0.0365)32,235

After-hours

Jul 22, 2026 4:57:30 PM EDT

0.9099USD+1.167%(+0.0105)38,633

OverviewOptionsHistoricalExchangesShortsNews

Jan 27, 2022

05:01AM EST 41 Biggest Movers From Yesterday Benzinga

Jan 7, 2022

08:00AM EST Rani Therapeutics Appoints Lisa Rometty to Board of Directors GlobeNewswire Inc

Nov 12, 2021

04:05PM EST Rani Therapeutics Appoints Lyn Baranowski to Board of Directors GlobeNewswire Inc

Sep 23, 2021

04:05PM EDT Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the companys Chief Executive Officer, Talat Imran, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 30, 2021, at 9:00 a.m. PT / 12:00 p.m. ET. GlobeNewswire Inc

Sep 13, 2021

04:08PM EDT Rani Therapeutics Hldgs Q2 EPS $(0.12) Down From $(0.06) YoY, Sales $1.96M Up From $60.00K YoY Benzinga

04:05PM EDT - IPO in July 2021 raised $84.3 million in gross proceeds -- Talat Imran Appointed Chief Executive Officer -- Enhanced leadership team with key management and board of directors appointments - GlobeNewswire Inc

Sep 9, 2021

08:00AM EDT Rani Therapeutics Holdings, Inc. (Rani Therapeutics or Rani) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the appointment of Eric Groen as General Counsel. Mr. Groen has more than 25 years of experience managing legal matters in corporate and private practice. GlobeNewswire Inc

Aug 25, 2021

10:07AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2021 Benzinga

07:58AM EDT BTIG Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $24 Benzinga

Aug 24, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2021 Benzinga

07:28AM EDT B of A Securities Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $23 Benzinga

07:23AM EDT Cantor Fitzgerald Initiates Coverage On Rani Therapeutics Hldgs with Overweight Rating, Announces Price Target of $23 Benzinga

07:18AM EDT Stifel Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $24 Benzinga

Aug 13, 2021

04:05PM EDT Rani Therapeutics Announces Closing of its Initial Public Offering GlobeNewswire Inc

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 11, 2021

12:12PM EDT Mid-Day Market Update: Upstart Jumps Following Strong Q2 Results; ON24 Shares Slide Benzinga

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Jul 30, 2021

03:49PM EDT Rani Therapeutics Debuts On The Nasdaq: What You Should Know About The Biopharma Benzinga

12:08PM EDT Rani Therapeutics Holdings Shares Open For Trade At $11.26; IPO Priced $11/Share Benzinga

09:15AM EDT Rani Therapeutics Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $11/Share Benzinga

08:56AM EDT Rani Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire Inc

Share